Tissue and organ Engineering and Manufacturing
2.4K views | +0 today
Follow
 
Rescooped by Carlos Garcia Pando from Medical Engineering = MEDINEERING
onto Tissue and organ Engineering and Manufacturing
Scoop.it!

FALSE ---Cornell Chronicle: Engineers 3-D print artificial ear

FALSE ---Cornell Chronicle: Engineers 3-D print artificial ear | Tissue  and organ Engineering and Manufacturing | Scoop.it
Cornell bioengineers and physicians have created an artificial ear - using 3-D printing and injectable molds - that looks and acts like a natural ear.
more...
Carlos Garcia Pando's curator insight, February 22, 2013 1:09 PM

3D scanning and modeling, 3D-printing a mold, cast a suitable collagen gel full of cartillage cells and after some days it can be implanted and nurtured from the host body

.

The process is smart enough, cute enough, clever enough, and amazing enough without the need of lying about it

 

Please, this attitude of rising false expectations hurts research

Tissue  and organ Engineering and Manufacturing
How to make living organs, not artificial
Your new post is loading...
Your new post is loading...
Scooped by Carlos Garcia Pando
Scoop.it!

Stanford researchers improve understanding of COLLAGEN,  could improve bioengineered tissues

Stanford researchers improve understanding of COLLAGEN,  could improve bioengineered tissues | Tissue  and organ Engineering and Manufacturing | Scoop.it
New insights into the characteristics of collagen, the protein that provides structure and stability for cells but which also stretches like Silly Putty, could help scientists design techniques for regenerating tissues.
Carlos Garcia Pando's insight:
Great material to master and use for bioprinting.
more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

skin cells reprogrammed to kill glioblastoma cells

skin cells reprogrammed to kill glioblastoma cells | Tissue  and organ Engineering and Manufacturing | Scoop.it

Skin cells turned cancer-killing stem cells hunt down and destroy the deadly remnants inevitably left behind when a brain tumor is surgically removed

 

Carlos Garcia Pando's insight:

"In summary, our results provide the first evidence that iNSC can treat diseases of the CNS and demonstrate the feasibility and efficacy of iNSC-based therapy for GBM. We found that iNSCs migrate to GBM, secrete anticancer molecules and regress GBM with the same efficiency as WTNSC drug carriers. Stem cell-based therapy for GBM has recently entered clinical trials for primary and recurrent GBM, and trials for breast cancer and neuroblastoma will be launched soon. With continued development, iNSC technology will have an impact on the design of these trials as a viable alternative drug-delivery vehicle with the potential for autologous treatment."

more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

Scientists Prove Feasibility of “Printing” Replacement Tissue

Scientists Prove Feasibility of “Printing” Replacement Tissue | Tissue  and organ Engineering and Manufacturing | Scoop.it
 Using a sophisticated, custom-designed 3D printer, Wake Forest Baptist regenerative
medicine scientists  have proved that it is feasible
to print living tissue structures to replace injured or diseased tissue in
patients.
Carlos Garcia Pando's insight:

Several proof-of-concept experiments demonstrated the capabilities of ITOP. To show that ITOP can generate complex 3D structures, printed, human-sized external ears were implanted under the skin of mice. Two months later, the shape of the implanted ear was well-maintained and cartilage tissue and blood vessels had formed. 

more...
No comment yet.
Rescooped by Carlos Garcia Pando from Amazing Science
Scoop.it!

Artificial intestines created including nutrient-absorbing villi that might help humans with gut disorders

Artificial intestines created including nutrient-absorbing villi that might help humans with gut disorders | Tissue  and organ Engineering and Manufacturing | Scoop.it

David Hackam spends much of his work day at the Johns Hopkins Children’s Center removing blackened sections of dead intestine from sick babies. But someday the pediatric surgeon may have a way to restore ravaged intestines—thanks to his work growing the organ in the lab. Starting with stem cells from the small intestines of human infants and mice, Hackam and his colleagues have for the first time grown intestinal linings on gut-shaped scaffolds that could one day treat bowel disorders like necrotizing enterocolitis and Crohn’s disease. They have found that the tissue and scaffolding are not rejected, but instead readily assimilate in lab animals. Most strikingly, the scaffold allowed dogs to heal from damage to the colon lining, restoring healthy bowel function.

 

The study is a “great breakthrough,” says Hans Clevers, a stem cell biologist at the Hubrecht Institute in Utrecht, the Netherlands, who was not involved in the new research. Clevers was the first to identify stem cells in the intestine, and his lab developed the technique Hackam’s team used to grow intestinal tissue.

 

The idea of making replacement organs by growing cells on a scaffold is not new; other researchers have done so with bladders and blood vessels. But Hackam’s lab-grown intestine—described last week in Regenerative Medicine—comes closer to the shape and structure of a natural intestine than anything created before. In the past, gut lining has been grown on flat scaffolds or petri dishes, where it tended to curl into little balls with the food-absorbing surface trapped inside.

 

Hackam’s group overcame that with their scaffold, made from a material similar to surgical sutures that can be formed into any desired intestinal size and shape. Hackam’s scaffolds are tube-shaped like a real gut, with tiny projections on the inner surface to help the tissue grow into functional small intestine villi, tiny fingers of tissue that help absorb nutrients. “They can now make sheets of cells that can be clinically managed,” Clevers says. “Surgeons can handle these things and just stick them in.”

 

To grow the gut lining in the lab, the researchers painted the scaffold with a sticky substance containing collagen, dribbled it with a solution of small intestine stem cells, and then let it incubate for a week. They found that adding connective tissue cells, immune cells, and probiotics—bacteria that help maintain a healthy gut—helped stem cells mature and differentiate.

 

In one set of experiments, the researchers sewed intestines grown from mouse stem cells into the tissue surrounding the mice’s abdominal organs. The lab-grown intestines developed their own blood supply and normal gut structures, even though they were not connected to the animals’ digestive tract. “Using the mouse's own stem cells, we can actually create something that looks just like the native intestine,” Hackam says. The next step, he says, is “to hook it up.”

 

First, though, they set out to test the new scaffold in dogs. Because the end of the digestive tract is easier to access than the small intestine, the researchers removed sections of colon lining from dogs and replaced it with pieces of scaffolding. The dogs made a complete recovery: Their gut lining regrew onto the scaffold and functioned normally to absorb water from the colon. Within weeks, the scaffolding dissolved and was replaced with normal connective tissue. “The scaffold was well tolerated and promoted healing by recruiting stem cells,” Hackam says. “[The dogs] had a perfectly normal lining after 8 weeks.”


Via Dr. Stefan Gruenwald
more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

Pancreatic cancer breakthrough: scientists turn cancer cells into normal cells

Pancreatic cancer breakthrough: scientists turn cancer cells into normal cells | Tissue  and organ Engineering and Manufacturing | Scoop.it

“Presently, pancreatic adenocarcinoma is treated with cytotoxic agents, yet the average survival for  patients post-diagnosis is merely six months, and the improvements in therapies are measured in days,”


Carlos Garcia Pando's insight:

Pancreatic adenocarcinoma is the most common form of pancreatic cancer. It’s primarily caused by a mutation in the oncogene called Kras that causes the digestive enzyme-secreting cells (acinar cells) to differentiate into a destabilized duct-like cell type, which is cancerous. The disease is often called a “silent” cancer because it rarely shows early symptoms—it tends to be diagnosed at advanced stages when it causes weight loss, abdominal pain, and jaundice.

 

more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

Tissue Engineering & Bioprinting: Research to Commercialization Agenda

Tissue Engineering & Bioprinting: Research to Commercialization Agenda | Tissue  and organ Engineering and Manufacturing | Scoop.it
Carlos Garcia Pando's insight:

This is a must go for all interested in bio-printing.

Featruring those behind the quantum leaps forward in tissue engineering and manufacturing

more...
No comment yet.
Rescooped by Carlos Garcia Pando from Stem Cells & Tissue Engineering
Scoop.it!

Liver cells grown with new reprogramming method

Liver cells grown with new reprogramming method | Tissue  and organ Engineering and Manufacturing | Scoop.it

Via Jacob Blumenthal
more...
Jacob Blumenthal's curator insight, February 24, 2014 11:48 AM

Researchers from the Gladstone institute published a new method for generation of functional hepatocytes from human fibroblast cells. In the new method, they directly reprogrammed fibroblast cells towards hepatic faith, without going through an iPSC, pluripotent stage. In order to test their functionality, the induced hepatic cells were transplanted into mouse models of liver failure where they  proliferated and displayed hepatic functionality.

Full paper:

http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13020.html


Learn more about liver development and stem cell protocols:

http://discovery.lifemapsc.com/in-vivo-development/liver




Rescooped by Carlos Garcia Pando from Cell Therapy & Regenerative Medicine
Scoop.it!

Stem cells made quickly in acid in possible game-changing technique

Stem cells made quickly in acid in possible game-changing technique | Tissue  and organ Engineering and Manufacturing | Scoop.it
Stem cells made quickly in acid in possible game-changing technique
CBS News
This image from the journal Nature shows a mouse embryo formed with specially-treated cells from a newborn mouse that had been transformed into stem cells.

Via Ella Buzhor
Carlos Garcia Pando's insight:

Once again, a simple as breathing method for performing a complex task bringing amazing results. Who was that who said "any stupid can do complex things, but you need a genius to make it simple"?

more...
Ella Buzhor's curator insight, January 30, 2014 6:59 AM

Stimulus-triggered acquisition of pluripotency (STAP) is the technique that enables somatic cell reprogramming into pluripotent cells by exposure to sublethal stimuli, without the need to introduce "Yamanaka" factors. This technique provides faster and safer way to yield higher quantities of pluripotent cells that might be further utilized for regenerative medicine.

I think that reprogramming technique maybe the game changer!!!


http://www.nature.com/nature/journal/v505/n7485/full/nature12969.html

Rescooped by Carlos Garcia Pando from Amazing Science
Scoop.it!

Cells silence X chromosomes in different patterns, sometimes skewing entire organs toward one parent

Cells silence X chromosomes in different patterns, sometimes skewing entire organs toward one parent | Tissue  and organ Engineering and Manufacturing | Scoop.it
Scientists have enlisted color coding in the effort to better understand X chromosomes, how they are shut down in certain cells and what it all means for men and women.

 

The X chromosome is part of the system that determines whether we become male or female. If an egg inherits an X chromosome from both parents, it becomes female. If it gets an X from its mother and a Y from its father, it becomes male.

 

But the X chromosome remains mysterious. For one thing, females shut down an X chromosome in every cell, leaving only one active. That’s a drastic step to take, given that the X chromosome has more than 1,000 genes.

 

In some cells, the father’s goes dormant, and in others, the mother’s does. While scientists have known about this so-called X-chromosome inactivation for more than five decades, they still know little about the rules it follows, or even how it evolved.

 

In the journal Neuron, a team of scientists has unveiled an unprecedented view of X-chromosome inactivation in the body. They found a remarkable complexity to the pattern in which the chromosomes were switched on and off.

 

In recent years, scientists have increasingly appreciated that our cells can vary genetically — a phenomenon called mosaicism. And X-chromosome inactivation, Dr. Nathans’s pictures show, creates a genetic diversity that’s particularly dramatic. Two cells side by side may be using different versions of many different genes. “But there is also much larger-scale diversity,” Dr. Nathans said.

 

In some brains, for example, a mother’s X chromosome was seen dominating the left side, while the father’s dominated the right. Entire organs can be skewed toward one parent. Dr. Nathans and his colleagues found that in some mice, one eye was dominated by the father and the other by the mother. The diversity even extended to the entire mouse. In some animals, almost all the X chromosomes from one parent were shut; in others, the opposite was true.


Via Dr. Stefan Gruenwald
Carlos Garcia Pando's insight:

INcredible.  
In some brains, for example, a mother’s X chromosome was seen dominating the left side, while the father’s dominated the right, so you cahn have both your mother's artistic sense and your father's acute abstract thinking power!

more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

DEPUY SYNTHES SPINE LAUNCHES NEW TISSUE IMPLANT FOR SPINE SURGERY, CONFORM SHEET™

Carlos Garcia Pando's insight:

The new allograft implant, processed by the Musculoskeletal Transplant Foundation (MTF), has both osteoinductive (encouraging undifferentiated cells to become active osteoblasts) and osteoconductive (guiding the reparative growth of the natural bone) properties. Through a demineralization process, bone morphogenic proteins (BMPs) are exposed, providing Conform Sheet its osteoinductive properties, while the cancellous structure of the scaffold provides osteoconductive characteristics. Conform Sheet is reportedly wickable: it readily absorbs various hydrating fluids including bone marrow aspirate, blood or saline. When combined with bone marrow aspirate, Conform Sheet becomes osteogenic (lays down new bone cells).

more...
No comment yet.
Rescooped by Carlos Garcia Pando from Stem Cells & Tissue Engineering
Scoop.it!

Defining Key Design Criteria for Cardiac Tissue Engineering

Defining Key Design Criteria for Cardiac Tissue Engineering | Tissue  and organ Engineering and Manufacturing | Scoop.it

Via Jacob Blumenthal
Carlos Garcia Pando's insight:

This is like the drawings and procedure. Sience is taking the engineering steps.

more...
Jacob Blumenthal's curator insight, December 5, 2013 2:50 AM

Cardiomyocytes, differentiated from either human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs), are used in cardiovascular research throughout the last decade. In addition to their regenerative capacities and promise for clinical application, these cells provide an unlimited source of...

(click the link below for the full story)

http://us4.campaign-archive1.com/?u=985051700e9649000fa0c0d4a&id=ed2c6547b5&e=f1b990f7f8

Scooped by Carlos Garcia Pando
Scoop.it!

FDA Grants Approval for Spinal Cord Injury Treatment Trial

FDA Grants Approval for Spinal Cord Injury Treatment Trial | Tissue  and organ Engineering and Manufacturing | Scoop.it
Carlos Garcia Pando's insight:

http://www.stemcellsinc.com/Science/Overview.htm


Earlier this year, StemCells reported that two of three patients with the worse kind of spinal cord injuries showed "considerable gains" in feeling sensations a year after receiving treatment.


StemCells is conducting a Phase I/II clinical trial of HuCNS-SC cells in Switzerland at the Balgrist University Hospital, University of Zurich, one of the leading medical centers in the world for spinal cord injury and rehabilitation.   The principal investigator is Armin Curt, MD, Professor and Chairman, Spinal Cord Injury Center at the University of Zurich, and Medical Director of the Paraplegic Center at the Balgrist University Hospital.   Dr. Curt is an internationally renowned medical expert in spinal cord injury.  The trial was initiated in March 2011, and is currently open for enrollment.

more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

Characterization of a biodegradable coralline hydroxyapatite/calcium carbonate composite and its clinical implementation - IOPscience

Characterization of a biodegradable coralline hydroxyapatite/calcium carbonate composite and its clinical implementation - IOPscience | Tissue  and organ Engineering and Manufacturing | Scoop.it
A partially converted, biodegradable coralline hydroxyapatite/calcium carbonate (CHACC) composite comprising a coral calcium carbonate scaffold enveloped by a thin layer of hydroxyapatite was used in the present study.
Carlos Garcia Pando's insight:

In conclusion, CHACC appears to be an excellent biodegradable bone graft material. It biointegrates with the host, is osteoconductive, biodegradable and can be an attractive alternative to autogenous grafts

more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

Faster way to harvest bone marrow stem cells, better for donors

Faster way to harvest bone marrow stem cells, better for donors | Tissue  and organ Engineering and Manufacturing | Scoop.it
A hematopoietic stem cell (HSC) being mobilised from the bone marrow microenvironment into a blood vessel.
Carlos Garcia Pando's insight:
Harvesting bone marrow stem cells in hours instead of days, and without side effects. Stem cell therapies a step closer
more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

Stem Cells Capable of specifically Repairing Skull and Face Bones

Stem Cells Capable of specifically Repairing Skull and Face Bones | Tissue  and organ Engineering and Manufacturing | Scoop.it

A team of Rochester scientists has, for the first time, identified and isolated a stem cell population capable of skull formation and craniofacial bone repair in mice—achieving an important step toward using stem cells for bone reconstruction of the face and head in the future,

Carlos Garcia Pando's insight:

Very interestingly, this team has demonstrated that stem cells within Axin2 cell populations are responsible for bone formation, repair and regeneration in the skull and face bones, and that separate and distinct stem cells are responsible for formation of long bones in the legs and other parts of the body, for example.

 

more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

Nano-shells deliver molecules that tell bone to repair itself

Nano-shells deliver molecules that tell bone to repair itself | Tissue  and organ Engineering and Manufacturing | Scoop.it
ANN ARBOR—Scientists at the University of Michigan have developed a polymer sphere that delivers a molecule to bone wounds that tells cells already at the injury site to repair the damage. Using the
Carlos Garcia Pando's insight:

Good idea: activating cells already present instead of injecting foreign materials

more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

New material for creating artificial blood vessels

New material for creating artificial blood vessels | Tissue  and organ Engineering and Manufacturing | Scoop.it
TU Wien and MedUni Vienna have developed artificial blood vessels, which are broken down by the body and replaced with its own tissue.
Carlos Garcia Pando's insight:

http://www.sciencedirect.com/science/article/pii/S1742706114003869

 

more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

MIPT Researchers Grow Cardiac Tissue on “Spider Silk” Substrate

MIPT Researchers Grow Cardiac Tissue on “Spider Silk” Substrate | Tissue  and organ Engineering and Manufacturing | Scoop.it
Genetically engineered fibers of the protein spidroin, which is the construction material for spider webs, has proven to be a perfect substrate for cultivating heart tissue cells, a group of researchers led by Professor Konstantin Agladze found.
Carlos Garcia Pando's insight:

Fantastic results. This will not only be useful for cardiac cells but for other organs also.

more...
No comment yet.
Scooped by Carlos Garcia Pando
Scoop.it!

Stem-Cell Treatment for Blindness Moving Through Patient Testin

Stem-Cell Treatment for Blindness Moving Through Patient Testin | Tissue  and organ Engineering and Manufacturing | Scoop.it
Advanced Cell Technology is testing a stem-cell treatment for blindness that could preserve vision and potentially reverse vision loss.
Carlos Garcia Pando's insight:

The treatment is based on retinal pigment epithelium (RPE) cells that have been grown from embryonic stem cells. A surgeon injects 150 microliters of RPE cells  under a patient’s retina, which is temporarily detached for the procedure.

The treatment will be tested both on patients with Stargardt’s disease (an inherited form of progressive vision loss that can affect children) and on those with age-related macular degeneration, the leading cause of vision loss among people 65 and older.

 

more...
No comment yet.
Rescooped by Carlos Garcia Pando from Stem Cells & Tissue Engineering
Scoop.it!

Stimulus-triggered fate conversion of somatic cells into pluripotency - Nature


Via Jacob Blumenthal
more...
Jacob Blumenthal's curator insight, January 30, 2014 1:14 AM

Researchers from Harvard medical school, report on a new method for generation of induced pluripotent stem cells (iPSC). This method is termed stimulus-triggered acquisition of pluripotency or STAP. The researchers suggest that a strong external stimuli such as a transient low-pH stressor can induce reprogramming of mammalian somatic cells, into  pluripotent cells. This could be a very big breakthrough in generation of iPSCS, that until now required nuclear transfer or introduction of transcription factors.

Reference: http://www.nature.com/nature/journal/v505/n7485/full/nature12968.html

 

Leran more about stem cells:

http://discovery.lifemapsc.com/stem-cell-differentiation

 

Join my Facebook group for more stem cell scoops:

https://www.facebook.com/groups/STEMCELLSNET/

 

Christopher Duntsch's curator insight, January 31, 2014 3:18 PM

This is fascinating and also just bizarre. Human Pluripotent Stem Cells by defintition iare getting more complex, more random. That does not mean the biology is not there, the approach does not work, but I am most happy when stem cell approaches are well studied, well defined, and rigorous. I do not think much of ESCs or IPSCs (or MSCs) for many reasons both obvious and subtle, but the stem cell biology is amazing. I remember when the first nature article was reported where skin cells were injected with OCT4, NANOG, STAT3, KLM5, and CMyc? That event led to the hypothesis that ESC biology was held in the master transcriptional regulators, especially NOS and NOS genes.  Then other approaches accomplished the same, such as simple epigenetic engineering. Small molecuale induction, culture conditions with modificatoins, etc. But this is just wild.I have not seen the article, and I am sure they do a good job explaining their results, but off the cuff I cannot imagine how this works. Acidic pH is not a strong stressor in my opinion, and I cannot extropolate biology from in vivo modeling to help me think about this (except intradiscal), but it is quite striking if true. Indeed, it is almost as if all those times while culturing cells and forgetting to change the media (with a drop in pH), I was making IPSCs. (bad humor) My only comment is to not get to excited just yet because they do not do much other than some basic assays to show ESC biology occuring.  A good start though. But still an unexpected and exciting response. I wish I had thought of that!

Rescooped by Carlos Garcia Pando from Cell Therapy & Regenerative Medicine
Scoop.it!

Standartization issues to be taken care for the development of cell therapy products

Standartization issues to be taken care for the development of cell therapy products | Tissue  and organ Engineering and Manufacturing | Scoop.it
To manufacture stem cells for cell therapy, standards for other materials critical for the cells' growth and survival must also be considered. (Do you know what ancillary materials are needed in order to manufacture a cell therapy?

Via Ella Buzhor
Carlos Garcia Pando's insight:

Wherever Standartization appears it means there is going to be a widespread industrialization process, and that there are already strong stake holders wanting to have an advantaged position to start the race.

 

But this is good for the industry in general.

more...
Christopher Duntsch's curator insight, January 25, 2014 10:24 AM

As a real world example, without naming the companies, at this time, there are two adult stem cell biotechnology companies that are very similar and of interest, pursuing the treatment of the same disease process and tissue anatomy. Company A is US based, and has the benefit of 8+ years of research, volumes of R&D and results / data, and all its data, IP, and outcomes, are documented, patented, and published. Company A has a more relevant / appropriate stem cell therapeutic, approach, and dose. Company A doses the tissue and disease process with 5 - 10*4 stem cells, and reports efficacy that ranges from 95% - 100%, and averages around 97% in all studies, and safety profiles that collectively considered to be near 100%. Conversely, company B is based in a very different geographic locale, and has fast tracked its R&D from literally announcing its intent, to entering clinical studies in less than 2 years. Company B has very little data to support its stem cell therapeutic, dosing, and approach. Company B doses the tissue and disease process with 5 x 10*7 cells (roughly 1000X higher than company A), and reports efficacy in some studies that is ~1-5%, and without detail admits in other studies no efficacy at all, and finally, reports a safety profile that is roughly 80 -90%. Company B is regulated in a very different area in the world and in a manner that is not rigorous, efficient, or consistent. Despite the dramatic differences between the two, company B continues to release financial reports, and press, that are positive and suggest present growth and real potential for growth going forward. Even more confusing, their valuation within the stock market they are publicly traded in, and public opinion of the company in general, by the public, current investors, and market analysts, remains stable, and at times even positive, and give the company a high valuation. These groups seem to be easily manipulated by efforts by the company to downplay negatives, explain away these results, and maintain a strong marketing front. I make the comparison here, to point out the relevance of my comments above for Pluristem Tx which similar in many respects to Company B, and to compare both to company A, US Biotec

Rescooped by Carlos Garcia Pando from Stem Cells & Tissue Engineering
Scoop.it!

Pluripotent stem cells in regenerative medicine: challenges and recent progress : Nature Reviews Genetics

Pluripotent stem cells in regenerative medicine: challenges and recent progress : Nature Reviews Genetics | Tissue  and organ Engineering and Manufacturing | Scoop.it

Via Jacob Blumenthal
more...
Jacob Blumenthal's curator insight, January 18, 2014 10:56 AM

A new review by Viviane Tabar & Lorenz Studer discuss recent achievements  in directed differentiation of pluripotent stem cells,  new technologies that have facilitated the success of pluripotent stem cells therapies and the remaining obstacles on the road towards developing pluripotent stem cell-based  therapies.

http://www.nature.com/nrg/journal/v15/n2/abs/nrg3563.html?lang=en?WT.ec_id=NRG-201402

 

To learn more about stem cells:

http://discovery.lifemapsc.com/stem-cell-differentiation

 

 

 

David O'Connell's curator insight, February 8, 2014 10:31 AM
Jacob Blumenthal's insight:

A new review by Viviane Tabar & Lorenz Studer discuss recent achievements  in directed differentiation of pluripotent stem cells,  new technologies that have facilitated the success of pluripotent stem cells therapies and the remaining obstacles on the road towards developing pluripotent stem cell-based  therapies.

http://www.nature.com/nrg/journal/v15/n2/abs/nrg3563.html?lang=en?WT.ec_id=NRG-201402

 

To learn more about stem cells:

http://discovery.lifemapsc.com/stem-cell-differentiation

Scooped by Carlos Garcia Pando
Scoop.it!

State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption

State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption | Tissue  and organ Engineering and Manufacturing | Scoop.it
more...
No comment yet.
Rescooped by Carlos Garcia Pando from Stem Cells & Tissue Engineering
Scoop.it!

Scientists make lung cells from human stem cells

Scientists make lung cells from human stem cells | Tissue  and organ Engineering and Manufacturing | Scoop.it

Via Jacob Blumenthal
more...
Jacob Blumenthal's curator insight, December 3, 2013 2:31 PM

Researchers from the  Columbia University Medical Center, published a new paper in Nature Bitechnology, describing a novel method for generation of functional lung cells from pluripotent stem cells. Their highly-efficient differentiation method resulted in the formation of clara, ciliated, type I and type II alveolar epithelial cells.

A link to the paper:

 http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.2754.html

 

To learn about the embryonic development of the lung and realted stem cell protocols: 

http://discovery.lifemapsc.com/in-vivo-development/lung

Rescooped by Carlos Garcia Pando from Cell Therapy & Regenerative Medicine
Scoop.it!

CryoShot®- off-the-shelf cell therapy for osteoarthritis-clinical trial

CryoShot®-  off-the-shelf cell therapy for osteoarthritis-clinical trial | Tissue  and organ Engineering and Manufacturing | Scoop.it

Regenerative medicine company Regeneus' (ASX: RGS) will use Japan’s new laws to fast-track the clinical trial and potential approval of its new human “off-the-shelf” CryoShot® cell therapy to treat osteoarthritis.


Via Ella Buzhor
more...
Ella Buzhor's curator insight, November 25, 2013 4:21 AM

CryoShot® is allogeneic human adipose-derived mesenchymal stem cells for treatment of osteoarthritis and other musculoskeletal conditions. It is on a way to accelerated cell therapy approval process in Japan.